{"generic":"Ustekinumab","drugs":["Stelara","Ustekinumab"],"mono":{"0":{"id":"929484-s-0","title":"Generic Names","mono":"Ustekinumab"},"1":{"id":"929484-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929484-s-1-4","title":"Adult Dosing","mono":"<ul><li>evaluate patients for TB (tuberculin skin test) prior to therapy; treatment of latent infection should be started prior to ustekinumab therapy<\/li><li><b>Crohn's disease (Moderate to Severe), Resistant to tumor necrosis factor antagonists:<\/b> initial, 6 mg\/kg IV at week 0; maintenance, 90 mg SUBQ at weeks 8 and 16 was administered in a clinical trial<\/li><li><b>Plaque psoriasis (Moderate to Severe):<\/b> patient weight 100 kg or less, 45 mg SUBQ initially and 4 weeks later, followed by 45 mg every 12 weeks<\/li><li><b>Plaque psoriasis (Moderate to Severe):<\/b> patient weight greater than 100 kg, 90 mg SUBQ initially and 4 weeks later, followed by 90 mg every 12 weeks<\/li><li><b>Psoriatic arthritis, Active, alone or in combination with methotrexate:<\/b> 45 mg SUBQ initially and 4 weeks later, followed by 45 mg SUBQ every 12 weeks<\/li><li><b>Psoriatic arthritis, Active, alone or in combination with methotrexate:<\/b> coexistent moderate to severe plaque psoriasis and weight greater than 100 kg (220 lbs), 90 mg SUBQ initially and 4 weeks later, followed by 90 mg SUBQ every 12 weeks<\/li><\/ul>"},"1":{"id":"929484-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"929484-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Plaque psoriasis (Moderate to Severe)<\/li><li>Psoriatic arthritis, Active, alone or in combination with methotrexate<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Crohn's disease (Moderate to Severe), Resistant to tumor necrosis factor antagonists<br\/>"}}},"3":{"id":"929484-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929484-s-3-9","title":"Contraindications","mono":"hypersensitivity, clinically significant, to ustekinumab or to any component of the product <br\/>"},{"id":"929484-s-3-10","title":"Precautions","mono":"<ul><li>allergic reactions, including angioedema and possible anaphylaxis, have been reported<\/li><li>allergy immunotherapy, concurrent or history, particularly with immunotherapy for anaphylaxis; increased risk for allergic reaction due to decreased protective effect<\/li><li>concomitant use with live vaccine not recommended<\/li><li>cutaneous squamous cell carcinomas have been reported; risk increases with preexisting risk factors, including age older than 60 years, a medical history of prolonged immunosuppressant therapy, or history of psoralen ultraviolet A (PUVA) therapy; monitoring recommended<\/li><li>elderly patients (aged 60 years or older); increased risk of malignancy; monitoring recommended<\/li><li>genetically deficient IL-12 and\/or IL-23 patients are vulnerable to disseminated infections from mycobacteria, salmonella, and bacillus Calmette-Guerin vaccinations; serious infections and fatal outcomes have been reported; appropriate diagnostic testing recommended as warranted by clinical situation<\/li><li>infections, serious (bacterial, fungal, and viral), some requiring hospitalization, have been reported; do not initiate therapy in patients with unresolved or inadequately treated active infections and use caution in patients with latent, chronic, or history of recurrent infections; discontinue therapy if a serious infection develops<\/li><li>latex sensitivity; needle cover on the prefilled syringe contains dry natural rubber, a derivative of latex<\/li><li>live vaccine administration to household contacts; potential risk for shedding from the household contact and transmission to patient<\/li><li>malignancies have been reported; safety has not been evaluated in patients with a known malignancy or a history of malignancy<\/li><li>prolonged immunosuppressant therapy, history of; increased risk of malignancy; monitoring recommended<\/li><li>psoralen ultraviolet A (PUVA) therapy, prior; increased risk of malignancy; monitoring recommended<\/li><li>reversible posterior leukoencephalopathy syndrome (RPLS) has been reported; discontinue therapy if RPLS is suspected<\/li><li>TB, pretreatment evaluation recommended; do not initiate ustekinumab in patients with active TB and initiate treatment for latent TB prior to administering ustekinumab<\/li><li>TB, history of latent or active disease in whom an adequate course of treatment cannot be confirmed; consider antituberculosis therapy prior to initiation of ustekinumab; monitoring recommended during and after treatment<\/li><li>vaccination with BCG 1 year prior to, during, or 1 year after discontinuation of therapy is not recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088, or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929484-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"929484-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929484-s-4","title":"Drug Interactions","sub":{"1":{"id":"929484-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (theoretical)<\/li><li>Adenovirus Vaccine Type 7, Live (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (theoretical)<\/li><li>Influenza Virus Vaccine, Live (theoretical)<\/li><li>Measles Virus Vaccine, Live (theoretical)<\/li><li>Mumps Virus Vaccine, Live (theoretical)<\/li><li>Poliovirus Vaccine, Live (theoretical)<\/li><li>Rotavirus Vaccine, Live (theoretical)<\/li><li>Rubella Virus Vaccine, Live (theoretical)<\/li><li>Smallpox Vaccine (theoretical)<\/li><li>Typhoid Vaccine (theoretical)<\/li><li>Varicella Virus Vaccine (theoretical)<\/li><li>Yellow Fever Vaccine (theoretical)<\/li><\/ul>"}}},"5":{"id":"929484-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Immunologic:<\/b>Infectious disease (27% to 72.3%)<\/li><li><b>Neurologic:<\/b>Headache (5%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (7% to 8%), Upper respiratory infection (4% to 5%)<\/li><li><b>Other:<\/b>Fatigue (3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Skin cancer, Non-melanoma (1.5%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction, Infectious disease, Serious infections (0.3% to 2.8%)<\/li><li><b>Neurologic:<\/b>Posterior reversible encephalopathy syndrome<\/li><li><b>Other:<\/b>Angioedema, Cancer (1.7%)<\/li><\/ul>"},"6":{"id":"929484-s-6","title":"Drug Name Info","sub":{"0":{"id":"929484-s-6-17","title":"US Trade Names","mono":"Stelara<br\/>"},"2":{"id":"929484-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"929484-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929484-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929484-s-7","title":"Mechanism Of Action","mono":"Ustekinumab is a human IgG1-kappa monoclonal antibody that binds to the p40 subunits of the interleukin (IL)-12 and IL-23 cytokines which are involved in inflammatory and immune responses.<br\/>"},"8":{"id":"929484-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929484-s-8-23","title":"Absorption","mono":"Tmax, subQ: 7 to 13.5 days <br\/>"},"1":{"id":"929484-s-8-24","title":"Distribution","mono":"<ul><li>Vd, IV: 56.1 to 82.1 mL\/kg<\/li><li>Vd, subQ: 161 to 179 mL\/kg<\/li><\/ul>"},"3":{"id":"929484-s-8-26","title":"Excretion","mono":"Total body clearance: 1.9 to 2.22 mL\/day\/kg <br\/>"},"4":{"id":"929484-s-8-27","title":"Elimination Half Life","mono":"14.9 to 45.6 days <br\/>"}}},"9":{"id":"929484-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>for subQ injection only<\/li><li>single-use vial: inject using a 27-gauge, 0.5-inch needle and rotate injection sites<\/li><li>prefilled syringe: inject full contents of syringe; maintain pressure on plunger head and remove from skin; slowly allow empty syringe to move up to cover needle with needle guard<\/li><li>avoid injections into tender, bruised, erythematous, or indurated skin<\/li><\/ul>"},"10":{"id":"929484-s-10","title":"Monitoring","mono":"<ul><li>psoriasis: improvement in psoriatic lesions is indicative of efficacy<\/li><li>psoriatic arthritis: normalization of serum C-reactive protein levels, improvement in the number of swollen or tender joints, or reduction in joint pain is indicative of efficacy<\/li><li>appearance of non-melanoma skin cancer; especially patients greater than 60 years of age, and patients with a history of prolonged immunosuppressant therapy or psoralen UV-A (PUVA) therapy<\/li><li>TB test; prior to initiating therapy<\/li><li>TB, active; signs or symptoms during and after therapy<\/li><\/ul>"},"11":{"id":"929484-s-11","title":"How Supplied","mono":"<b>Stelara<\/b><br\/>Subcutaneous Solution: 90 MG\/ML, 45 MG\/0.5 ML<br\/>"},"13":{"id":"929484-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause angioedema (ie, swelling of the face, lips, tongue, throat). Advise patient to seek immediate medical attention if one or more of these symptoms occur.<\/li><li>Advise patient that live vaccines are not to be taken during therapy due to drug-induced immunosuppression.<\/li><li>Advise patient to take caution with household members receiving live vaccines as viral shedding may result.<\/li><li> Patients should not receive the Bacille Calmette-Guerin (BCG) vaccine the one year before taking ustekinumab, during ustekinumab therapy, or one year after ustekinumab treatment is stopped.<\/li><li>Instruct patient to notify doctor immediately with symptoms of an infection.<\/li><li>Drug may cause nasopharyngitis, upper respiratory tract infection, headache, and fatigue.<\/li><li>Advise patient to notify doctor if symptoms of reversible posterior leukoencephalopathy syndrome (ie, headache, seizures, confusion, vision problems) occur.<\/li><li>Instruct patient to immediately report signs\/symptoms of hypersensitivity (eg, pruritus, erythema, flushing, urticaria, or other rash).<\/li><li>If appropriate, a patient or caregiver may administer the drug. Teach patient or caregiver proper injection technique and disposal. Supervise and evaluate first injection.<\/li><li>Needle cover on the single-use prefilled syringe contains latex. Patients sensitive to latex should not handle needle covers due to risk of allergic reaction.<\/li><\/ul>"}}}